HitGen : Dorian and HitGen Announce Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery
Message : Required fields Shanghai Stock Exchange listed company HitGen Inc. (“HitGen”) today announced that it has entered into a research collaboration agreement with Dorian Therapeutics, Inc. (“Dorian”), a private biotechnology company developing senoblockers, a new class of therapeutics that can rejuvenate cells and tissues. HitGen will apply its platform technology, based on the design, synthesis and screening of DNA-encoded libraries (DEL) to discover compounds that bind to certain targets that are of interest to Dorian. Under the terms of the agreement, HitGen will receive an u...